DE3119510A1 - "antitumormittel und verfahren zu deren herstellung" - Google Patents

"antitumormittel und verfahren zu deren herstellung"

Info

Publication number
DE3119510A1
DE3119510A1 DE19813119510 DE3119510A DE3119510A1 DE 3119510 A1 DE3119510 A1 DE 3119510A1 DE 19813119510 DE19813119510 DE 19813119510 DE 3119510 A DE3119510 A DE 3119510A DE 3119510 A1 DE3119510 A1 DE 3119510A1
Authority
DE
Germany
Prior art keywords
lactic acid
amsa
water
solution
molar ratio
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
DE19813119510
Other languages
German (de)
English (en)
Other versions
DE3119510C2 (enExample
Inventor
Daniel Bouzard
Murray Arthur Kaplan
Claude Perol
Jacques Stemer
Abraham Weber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Co filed Critical Bristol Myers Co
Publication of DE3119510A1 publication Critical patent/DE3119510A1/de
Application granted granted Critical
Publication of DE3119510C2 publication Critical patent/DE3119510C2/de
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE19813119510 1980-05-16 1981-05-15 "antitumormittel und verfahren zu deren herstellung" Granted DE3119510A1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/147,056 US4360523A (en) 1980-05-16 1980-05-16 Pharmaceutical formulations of 4'-(9-acridinylamino)-methanesulfon-m-anisidide

Publications (2)

Publication Number Publication Date
DE3119510A1 true DE3119510A1 (de) 1982-02-25
DE3119510C2 DE3119510C2 (enExample) 1991-03-07

Family

ID=22520148

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19813119510 Granted DE3119510A1 (de) 1980-05-16 1981-05-15 "antitumormittel und verfahren zu deren herstellung"

Country Status (21)

Country Link
US (1) US4360523A (enExample)
JP (1) JPS579716A (enExample)
AT (1) AT374682B (enExample)
AU (1) AU543726B2 (enExample)
BE (1) BE888832A (enExample)
CA (1) CA1160571A (enExample)
CH (1) CH647677A5 (enExample)
DE (1) DE3119510A1 (enExample)
DK (1) DK159376C (enExample)
FI (1) FI70793C (enExample)
FR (1) FR2482458A1 (enExample)
GB (1) GB2076288B (enExample)
GR (1) GR75658B (enExample)
IE (1) IE51285B1 (enExample)
IT (1) IT1170970B (enExample)
LU (1) LU83363A1 (enExample)
NL (1) NL8102362A (enExample)
NZ (1) NZ196985A (enExample)
SE (1) SE460457B (enExample)
YU (1) YU44831B (enExample)
ZA (1) ZA813188B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4575509A (en) * 1983-01-31 1986-03-11 Bristol-Myers Company Water-soluble formulations of m-AMSA with pyroglutamic acid
US4626541A (en) * 1985-09-12 1986-12-02 Bristol-Myers Company Water soluble salt composition of m-AMSA
DE3844518A1 (de) * 1988-03-23 1989-10-05 Karl Heinz Dr Med Thiel Verwendung von aminochinolinen und aminopyridinen zur iontophoretischen behandlung maligner tumore
DE3819842C1 (enExample) * 1988-03-23 1989-12-21 Karl Heinz Dr. 7100 Heilbronn De Thiel
CA2143515A1 (en) * 1994-03-22 1995-09-23 Prakash Parab Method for enhancing the rate of skin permeation of lactic acid through use of the l-enantiomer
WO2006002887A1 (en) * 2004-06-29 2006-01-12 Baxter International Inc. Aqueous drink solution of indibulin (d-24851) and an organic acid
DE102004031538A1 (de) * 2004-06-29 2006-02-09 Baxter International Inc., Deerfield Pharmazeutische Darreichungsform zur oralen Verabreichung eines schwerlöslichen Wirkstoffs, Verfahren zu deren Herstellung und Kit
WO2006052712A1 (en) * 2004-11-08 2006-05-18 Baxter International Inc. Nanoparticulate compositions of tubulin inhibitor
JP2010511041A (ja) * 2006-11-28 2010-04-08 ジオファーム オンコロジー， インコーポレイテッド インジブリンを含むインドリル−３−グリオキシル酸誘導体の癌を処置するための単独またはさらなる薬剤との組み合わせでの使用
WO2015150383A1 (en) * 2014-03-31 2015-10-08 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Glycolic acid and/or d-lactic acid for the treatment of neurodegenerative diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NICHTS ERMITTELT *

Also Published As

Publication number Publication date
IT8148467A1 (it) 1982-11-14
IE811092L (en) 1981-11-16
LU83363A1 (fr) 1982-01-20
JPH0136445B2 (enExample) 1989-07-31
FR2482458B1 (enExample) 1984-12-14
YU112381A (en) 1985-03-20
NL8102362A (nl) 1981-12-16
SE8103071L (sv) 1981-11-17
US4360523A (en) 1982-11-23
IT8148467A0 (it) 1981-05-14
BE888832A (fr) 1981-11-16
YU44831B (en) 1991-04-30
DK159376C (da) 1991-03-25
DK216681A (da) 1981-11-17
GR75658B (enExample) 1984-08-02
FI70793B (fi) 1986-07-18
GB2076288A (en) 1981-12-02
AU7029181A (en) 1981-11-19
SE460457B (sv) 1989-10-16
CA1160571A (en) 1984-01-17
NZ196985A (en) 1983-06-17
FI811474L (fi) 1981-11-17
IT1170970B (it) 1987-06-03
GB2076288B (en) 1983-12-14
DE3119510C2 (enExample) 1991-03-07
JPS579716A (en) 1982-01-19
FR2482458A1 (fr) 1981-11-20
ATA221181A (de) 1983-10-15
CH647677A5 (de) 1985-02-15
AT374682B (de) 1984-05-25
DK159376B (da) 1990-10-08
FI70793C (fi) 1986-10-27
ZA813188B (en) 1982-05-26
IE51285B1 (en) 1986-11-26
AU543726B2 (en) 1985-05-02

Similar Documents

Publication Publication Date Title
DE69627651T2 (de) Formulierungen und zusammensetzungen von in wasser schwer löslichen camptothecinderivaten
DE60209145T2 (de) Pharmazeutische formulierungen mit platinderivaten
DE69223624T2 (de) Taxan-derivate enthaltende arzneimittel
DE60114249T2 (de) Pharmazeutische zusammensetzung mit 2-(4-isobutylphenyl) propionsäure
DE68904922T2 (de) Piroxicam in waessrigen loesungen enthaltende arzneizubereitungen und verfahren zu deren herstellung.
EP0806955B1 (de) Enrofloxacin-injektions- oder infusionslösungen
DE68903814T2 (de) Etoposid-loesungen.
DE69633178T2 (de) Eisenverbindungen, zusammensetzungen, herstellungsverfahren und verwendungen davon
DE3119510A1 (de) "antitumormittel und verfahren zu deren herstellung"
DE60101979T2 (de) Lösung enthaltend N-[O-(p-pivaloyloxybenzenesulfonylamino)benzoyl]glyzin Mononatriumsalz Tetrahydrat und diese Lösung enthaltendes Arzneimittel
DE2945387C2 (enExample)
DE2335729A1 (de) Vincanolsalze, verfahren zu deren herstellung und diese verbindungen als wirkstoffe enthaltende pharmazeutische zubereitungen
DE3044736C2 (enExample)
DE2314387C3 (de) Arzneimittel zur Behandlung bösartiger Neubildungen
AT381024B (de) Verfahren zur herstellung eines pharmazeutischen mittels zur rekonstitution mit wasser
DE2716535A1 (de) Mittel zum schutz vor nierenversagen
DE3102026C2 (enExample)
DE102004052877B4 (de) Stabile wässrige Formulierungen eines Platin-Derivats
DE1792448C3 (de) Verfahren zur Herstellung von zur parenteralen Verabreichung geeigneten stabilen Lösungen von therapeutisch anwendbaren Benzodiazepinderivaten
DE2556001C3 (de) Spritzfertige injizierbare Lösungen mit einem Gehalt an Alkalicanrenoat
DE2633943A1 (de) Oral oder parenteral zu verabreichende loesung eines oxazepins
DE68909071T2 (de) Dialkyl-diselenide mit antineoplastischer Aktivität.
DE2809618A1 (de) Neues therapeutisches praeparat und verfahren zu dessen herstellung
DE2156056C3 (de) 3-tf',2'-Diphenyläthyl)-5-(2piperidino-äthyl)-1,2,4-oxadiazol-4-hydroxybenzoyl-benzoat-(2), dessen Herstellung und diese Verbindungen enthaltende Präparate
EP1738768B1 (de) Wässrige Formulierung für Vecuroniumbromid

Legal Events

Date Code Title Description
8110 Request for examination paragraph 44
8127 New person/name/address of the applicant

Owner name: BRISTOL-MYERS SQUIBB CO. (N.D.GES.D.STAATES DELAWA

8128 New person/name/address of the agent

Representative=s name: KINZEBACH, W., DIPL.-CHEM. DR.PHIL. RIEDL, P., DIP

D2 Grant after examination
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee